Greenwich LifeSciences, Inc.
GLSI
$11.67
-$0.26-2.18%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 3.58M | 3.40M | 3.06M | 1.64M | 1.54M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 18.14M | 16.76M | 16.01M | 10.76M | 10.54M |
Operating Income | -18.14M | -16.76M | -16.01M | -10.76M | -10.54M |
Income Before Tax | -17.99M | -16.57M | -15.79M | -10.50M | -10.22M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -17.99 | -16.57 | -15.79 | -10.50 | -10.22 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -17.99M | -16.57M | -15.79M | -10.50M | -10.22M |
EBIT | -18.14M | -16.76M | -16.01M | -10.76M | -10.54M |
EBITDA | -18.14M | -16.75M | -16.01M | -10.76M | -10.53M |
EPS Basic | -1.36 | -1.26 | -1.21 | -0.81 | -0.79 |
Normalized Basic EPS | -0.85 | -0.79 | -0.76 | -0.51 | -0.50 |
EPS Diluted | -1.36 | -1.26 | -1.21 | -0.81 | -0.79 |
Normalized Diluted EPS | -0.85 | -0.79 | -0.76 | -0.51 | -0.50 |
Average Basic Shares Outstanding | 52.83M | 52.37M | 52.06M | 51.76M | 51.46M |
Average Diluted Shares Outstanding | 52.83M | 52.37M | 52.06M | 51.76M | 51.46M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |